<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ethambutol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ethambutol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ethambutol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9430" href="/d/html/9430.html" rel="external">see "Ethambutol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11207" href="/d/html/11207.html" rel="external">see "Ethambutol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24520118"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Myambutol</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866809"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Etibi</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1047287"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antitubercular Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F168068"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97ac6a05-38e1-4b48-b518-54076eba0185">Mycobacterial infection, nontuberculous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial infection, nontuberculous:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycobacterium avium complex (MAC) infection in patients who are HIV-exposed/-infected:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Treatment: <b>Note: </b>Treatment should continue for at least 12 months and should be followed by secondary prophylaxis.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: 15 to 25 mg/kg/dose once daily as part of an appropriate combination regimen; maximum dose: 2,500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 15 mg/kg/dose once daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Secondary prophylaxis (chronic maintenance therapy):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: 15 to 25 mg/kg/dose once daily as part of an appropriate combination regimen; maximum dose: 2,500 mg/dose. May be discontinued if patient has completed ≥6 months of antiretroviral therapy and ≥12 months of MAC therapy, has no signs and symptoms of MAC, and achieves age-specific CD4 count goals for ≥6 months (age 2 to &lt;6 years: &gt;200 cells/mm<sup>3</sup>; ≥6 years: &gt;100 cells/mm<sup>3</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 15 mg/kg/dose once daily as part of an appropriate combination regimen. May be discontinued if patient has completed ≥12 months of MAC therapy, has no signs and symptoms of MAC, and has CD4 count &gt;100 cells/mm<sup>3</sup> in response to antiretroviral therapy for &gt;6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary infection in patients with cystic fibrosis:</i> Infants, Children, and Adolescents: Oral: 15 mg/kg/dose once daily as part of an appropriate combination regimen for ≥12 months after culture conversion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26666259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary infection in patients without cystic fibrosis: </i>Infants, Children, and Adolescents: Oral: 20 mg/kg/dose once daily as part of an appropriate combination regimen for ≥12 months after culture conversion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29054853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29054853'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8bd72a7e-53c8-425e-b06f-3999ca2c39e7">Tuberculosis disease [active tuberculosis]; drug-susceptible</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis disease (active tuberculosis); drug-susceptible (excluding meningitis): Note:</b> Treatment regimens for active tuberculosis typically consist of an initial 2-month intensive phase of a 4-drug regimen (including ethambutol, although a full 2 months of ethambutol may not be necessary), followed by a 2-drug regimen continuation phase (not including ethambutol); see guidelines for details and duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-WHO.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-WHO.5'])">Ref</a></span>). Always use in combination with other antitubercular drugs. Any regimens using less than once-daily dosing should be administered as directly observed therapy (DOT).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Once-daily therapy</i>: <b>Note: </b>The preferred frequency of administration is once daily; however, 5-days-per-week administration by DOT at the same daily dose is an acceptable alternative.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents, weighing &lt;40 kg: Oral: 20 mg/kg/dose once daily; suggested range: 15 to 25 mg/kg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents, weighing ≥40 kg: <b>Note:</b> Doses should be based on <b>lean</b> body weight for patients within a normal weight range for their height (optimal dosing in obesity has not been established).</p>
<p style="text-indent:-2em;margin-left:8em;">40 to 55 kg: Oral: 800 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">56 to 75 kg: Oral: 1,200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">76 to 90 kg: Oral: 1,600 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Three-times-weekly DOT: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents, weighing &lt;40 kg: Oral: 50 mg/kg/dose 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents, weighing ≥40 kg: <b>Note: </b>Doses should be based on <b>lean</b> body weight for patients within a normal weight range for their height (optimal dosing in obesity has not been established).</p>
<p style="text-indent:-2em;margin-left:8em;">40 to 55 kg: Oral: 1,200 mg 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">56 to 75 kg: Oral: 2,000 mg 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">76 to 90 kg: Oral: 2,400 mg 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Twice-weekly DOT: </i>
<b>Note:</b> Regimen not generally recommended; associated with worse outcomes (treatment failure, relapse, and drug resistance) compared to daily dosing. Do not use in patients with HIV or those with smear-positive and/or cavitary disease; only for use in continuation phase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-28203783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-28203783'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents, weighing &lt;40 kg: Oral: 50 mg/kg/dose twice weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents, weighing ≥40 kg: <b>Note:</b> Doses should be based on <b>lean</b> body weight for patients within a normal weight range for their height (optimal dosing in obesity has not been established).</p>
<p style="text-indent:-2em;margin-left:8em;">40 to 55 kg: Oral: 2,000 mg twice weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">56 to 75 kg: Oral: 2,800 mg twice weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">76 to 90 kg: Oral: 4,000 mg twice weekly.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3a3b13a-fb0f-4967-bfab-42233a97617a">Tuberculosis disease [active tuberculosis]; drug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis disease (active tuberculosis); drug-resistant: Note: </b>Duration should be individualized based on extent of disease, rapidity of culture conversion, clinical response, and toxicity; expert consultation for optimal regimen and duration of treatment is advised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 20 to 25 mg/kg/dose once daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109579"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Therapeutic drug monitoring should be utilized, when possible, in patients with severe kidney impairment or receiving renal replacement therapies to avoid drug accumulation and adverse effects, such as optic neuropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24846578','lexi-content-ref-29054853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24846578','lexi-content-ref-29054853'])">Ref</a></span>). There are no clinical or pharmacokinetic data to support a renal dosage adjustment recommendation for dosing strategies other than once-daily dosing; dosing recommendations derived from adult guideline recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-31729908','lexi-content-ref-HHS.2020','lexi-content-ref-25320836']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-31729908','lexi-content-ref-HHS.2020','lexi-content-ref-25320836'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Oral: 15 to 25 mg/kg/dose 3 times weekly.</p></div>
<div class="block dohp drugH1Div" id="F51109580"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doa drugH1Div" id="F168051"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9430" href="/d/html/9430.html" rel="external">see "Ethambutol: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b68a4e1b-80b5-4ec3-bd49-b20cb3f5bd4a">
<i>Mycobacterium avium</i> complex disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Mycobacterium avium </b></i>
<b>complex</b>
<b> disease (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary disease (nodular/bronchiectatic disease):</i>
<b>Oral:</b> 25 mg/kg 3 times weekly as part of an appropriate combination regimen; continue treatment until patient is culture negative on therapy for ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary disease (severe nodular/bronchiectatic or cavitary disease):</i>
<b>Oral:</b> 15 mg/kg once daily as part of an appropriate combination regimen; continue treatment until patient is culture negative on therapy for ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Disseminated disease in patients with HIV, treatment and chronic maintenance therapy</i>: <b>Oral: </b>15 mg/kg once daily in combination with a macrolide (azithromycin or clarithromycin); may discontinue when patient has completed ≥12 months of therapy, has no signs/symptoms of <i>M. avium</i> complex disease, and has sustained (&gt;6 months) CD4 count &gt;100 cells/mm<sup>3</sup> in response to antiretroviral therapy (ART). <b>Note:</b> Addition of a third or fourth drug should be considered for patients with advanced immunosuppression (CD4 count &lt;50 cells/mm<sup>3</sup>), high mycobacterial loads (&gt;2 log<sub>10</sub> CFU/mL), or in the absence of effective ART (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a53cbec7-9140-4e30-a67a-8aabf6d93e6d">Tuberculosis, drug-susceptible</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, drug-susceptible:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Always administer in combination with other antitubercular drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosing: </i>Doses should be based on <b>lean</b> body weight for patients within a normal weight range for their height (optimal dosing for patients with obesity has not been established):</p>
<p style="text-indent:-2em;margin-left:6em;">Once-daily therapy: <b>Note:</b> The preferred frequency of administration is once daily; however, 5-days-per-week administration by directly observed therapy (DOT) is an acceptable alternative (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">40 to 55 kg: <b>Oral:</b> 800 mg (14.5 to 20 mg/<b>kg</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">56 to 75 kg: <b>Oral: </b>1.2 g (16 to 21.4 mg/<b>kg</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">76 to 90 kg: <b>Oral: </b>1.6 g (17.8 to 21.1 mg/<b>kg</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Three-times-weekly DOT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">40 to 55 kg: <b>Oral: </b>1.2 g (21.8 to 30 mg/<b>kg</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">56 to 75 kg: <b>Oral: </b>2 g (26.7 to 35.7 mg/<b>kg</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">76 to 90 kg: <b>Oral: </b>2.4 g (26.7 to 31.6 mg/<b>kg</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Twice-weekly DOT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">40 to 55 kg: <b>Oral: </b>2 g (36.4 to 50 mg/<b>kg</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">56 to 75 kg: <b>Oral: </b>2.8 g (37.3 to 50 mg/<b>kg</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">76 to 90 kg: <b>Oral: </b>4 g (44.4 to 52.6 mg/<b>kg</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Regimens:</i> Treatment regimens for pulmonary tuberculosis consist of an initial 2-month phase of a 4-drug regimen that includes ethambutol, followed by a continuation phase consisting of a 2-drug regimen (does not include ethambutol) of an additional 4 to 7 months; ethambutol frequency and dosing differs depending on treatment regimen selected; consult current drug-susceptible TB guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c2940f0-014f-4362-aba1-d832529ab519">Tuberculosis, drug resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, drug resistant (alternative agent): Note:</b> Expert consultation for optimal regimen and duration of treatment is advised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Low dose (companion drug): <b>Oral: </b>15 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">High dose (bacteriostatic drug): <b>Oral: </b>25 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992009"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Therapeutic drug monitoring should be utilized, when possible, in patients with severe kidney impairment or on renal replacement therapies to avoid drug accumulation and adverse effects, such as optic neuropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24846578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24846578'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function </b>(expert opinion derived from ATS/CDC/IDSA [Nahid 2016]; AST/CDC/ERS/IDSA [Nahid 2019]; HHS [OI Adult 2020]; WHO 2014b):</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: If usual recommended dose is administered once daily, then do not adjust the dose, but only administer 3 times weekly (eg, if usual dose is 15 mg/kg once daily, then administer 15 mg/kg 3 times weekly; if usual dose is 25 mg/kg once daily, then administer 25 mg/kg 3 times weekly). Since there are no clinical or pharmacokinetic data to support a renal dosage adjustment recommendation for dosing strategies other than once daily dosing (eg, the directly observed therapy [DOT] twice-weekly or 3-times–weekly dosing described in patients with normal kidney function) use of these dosing strategies are not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (extent not well characterized) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28396542','lexi-content-ref-10228130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28396542','lexi-content-ref-10228130'])">Ref</a></span>): Dose as CrCl &lt;30 mL/minute; administer after hemodialysis on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-HHS.2','lexi-content-ref-25320836']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-HHS.2','lexi-content-ref-25320836'])">Ref</a></span>). Use with caution and close monitoring, as hemodialysis patients may develop optic adverse effects, even with properly adjusted doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24196753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24196753'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Likely dialyzable, but not considered a major route of removal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): Dose as for CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-29776936','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-29776936','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use with caution and close monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29776936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29776936'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse effects (eg, optic neuropathy) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Has not been studied in patients undergoing CRRT; some drug removal is expected but relatively large V<sub>d</sub> will likely prevent substantial removal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dose as for CrCl &lt;30 mL/minute; utilize therapeutic monitoring when possible to guide further dose adjustments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse effects (eg, optic neuropathy) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Limited data available in patients undergoing PIRRT; some drug removal is expected, but relatively large V<sub>d</sub> will likely prevent substantial removal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Recommendations assume daily PIRRT sessions.</p>
<p style="text-indent:-2em;margin-left:4em;">Dose as for CrCl &lt;30 mL/minute; on PIRRT days, administer after the PIRRT session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Utilize therapeutic monitoring, when possible, to guide further dose adjustments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26518065','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26518065','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989255"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F168016"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Adverse reactions may be reported as part of combination therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis, erythema multiforme, lichenoid eruption (Grossman 1995), pruritus (Chung 2022), skin lesion (bullous) (Kollipara 2022), skin rash (Chung 2022), Stevens-Johnson syndrome (Chung 2022), toxic epidermal necrolysis (Pegram 1981)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acute gout attack, increased uric acid (Chung 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (Chung 2022), anorexia (Chung 2022), gastric distress, nausea (Chung 2022), vomiting (Chung 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Moon 2015), eosinophilia (Wong 1994), leukopenia (Chung 2022), neutropenia (Wong 1994), thrombocytopenia (Chung 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (Chung 2022), hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Kapur 2019), hypersensitivity reaction (including anaphylaxis, nonimmune anaphylaxis) (Cernadas 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion, disorientation, dizziness (Chung 2022), headache (Chung 2022), malaise (Chung 2022), peripheral neuritis (numbness, tingling of extremities), psychotic symptoms (including hallucination) (Prasad 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (Chung 2022), subacute cutaneous lupus erythematosus (Huang 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuropathy (including optic neuritis and retrobulbar neuritis) (Chan 2006; Kyncl 2023), visual disturbance (including color blindness, decreased visual acuity [unilateral or bilateral], irreversible blindness, scotoma) (Kyncl 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (García-Martín 1991), acute kidney injury (Kwon 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis (including eosinophilic pneumonitis) (Saha 2013; Takami 1997), pulmonary infiltrates (with or without eosinophilia) (Wong 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Chung 2022)</p></div>
<div class="block coi drugH1Div" id="F168030"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ethambutol or any component of the formulation; optic neuritis (risk vs benefit decision); use in young children, unconscious patients, or any other patient who may be unable to discern and report visual changes.</p></div>
<div class="block war drugH1Div" id="F168013"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic toxicity: Has been reported, possibly due to concurrent therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Optic neuritis: May cause optic neuritis (unilateral or bilateral), resulting in decreased visual acuity or other vision changes. Discontinue promptly in patients with changes in vision, color blindness, or visual defects (effects normally reversible, but reversal may require up to a year). Irreversible blindness has been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Evaluation of visual acuity changes may be more difficult in patients with cataracts, optic neuritis, diabetic retinopathy, and inflammatory conditions of the eye; consideration should be given to whether or not visual changes are related to disease progression or effects of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage modification recommended.</p></div>
<div class="block foc drugH1Div" id="F168024"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myambutol: 400 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 400 mg</p></div>
<div class="block geq drugH1Div" id="F168009"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F168032"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ethambutol HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.46 - $0.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $0.72 - $1.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Myambutol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $0.98</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866810"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Etibi: 100 mg, 400 mg [contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p></div>
<div class="block admp drugH1Div" id="F52612758"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food; if GI upset occurs, administer with food. Tablet may be crushed for administration in patients who cannot swallow tablets; mix in a small amount of water or food (eg, grape jelly, sugar-free chocolate pudding) and administer immediately; may be administered via mouth or nasogastric tube (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-26810651','lexi-content-ref-35168714','lexi-content-ref-17638210','lexi-content-ref-35466379','lexi-content-ref-WHO.6']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-26810651','lexi-content-ref-35168714','lexi-content-ref-17638210','lexi-content-ref-35466379','lexi-content-ref-WHO.6'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F54671074"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food.</p></div>
<div class="block sts drugH1Div" id="F168043"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at controlled room temperature of 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53566802"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of pulmonary tuberculosis in combination with other antituberculosis agents (FDA approved in ages ≥13 years and adults); has also been used for the treatment of other mycobacterial diseases in combination with other antimycobacterial agents.</p></div>
<div class="block mst drugH1Div" id="F168094"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myambutol may be confused with Nembutal</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299290"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT1, OCT2</p></div>
<div class="block dri drugH1Div" id="F168018"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: May decrease the serum concentration of Ethambutol. Management: Avoid concurrent administration of ethambutol and aluminum hydroxide. If coadministration cannot be avoided administer ethambutol first and then wait at least 4 hours before administering aluminum hydroxide-containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54898468"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to treatment of multidrug-resistant tuberculosis in females of reproductive potential. Females of reproductive potential should use effective contraception during treatment for multidrug-resistant tuberculosis (Esmail 2018).</p></div>
<div class="block pri drugH1Div" id="F168033"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ethambutol crosses the placenta (Shneerson 1979).</p>
<p style="text-indent:0em;margin-top:2em;">In 1 case report, ethambutol placental concentrations were similar to those in the maternal plasma. Ethambutol was also present in the cord blood and amniotic fluid (Shneerson 1979).</p>
<p style="text-indent:0em;margin-top:2em;">Ophthalmic abnormalities have been reported in infants born to patients receiving ethambutol as a component of antituberculosis therapy. Tuberculosis (TB) disease (active TB) is also associated with adverse fetal outcomes including intrauterine growth restriction, low birth weight, preterm birth, and perinatal death (Esmail 2018; Miele 2020) as well as adverse maternal outcomes, including increased risks for anemia and cesarean delivery. Placental transmission may rarely occur with active maternal disease (Miele 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Due to the risks of untreated TB, ethambutol is recommended as part of the initial treatment regimen of drug-susceptible active TB when the probability of maternal disease is moderate to high (ATS/CDC/IDSA [Nahid 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Ethambutol may also be used to treat multidrug-resistant TB. The treatment of multidrug-resistant TB in patients who are pregnant should be individualized; evidence to support a specific regimen is not available (ATS/CDC/ERS/IDSA [Nahid 2019]; WHO 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnancy-induced physiologic changes do not alter the pharmacokinetic properties of ethambutol in a clinically significant way; dose adjustment is not needed in patients who are pregnant (Abdelwahab 2020).</p></div>
<div class="block mopp drugH1Div" id="F53566790"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline and periodic (monthly) examination of visual acuity and color discrimination in patients receiving &gt;15 mg/kg/day; baseline and periodic renal, hepatic, and hematologic function tests. Young children may be unable to report vision changes; monitor for eye rubbing or excessive blinking, or decrease in ability to grasp small objects (Loeffler 2022). Therapeutic drug monitoring (if available) should be considered in certain scenarios (eg, altered kidney function, possible malabsorption).</p></div>
<div class="block rerp drugH1Div" id="F58080945"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Ethambutol concentration monitoring is not routine but should be considered in certain scenarios (eg, altered kidney function, possible malabsorption) (Alsultan 2014; BTS [Haworth 2017]). The following target concentrations have been described in pharmacokinetic studies, but risks and benefits of achieving targets in pediatric patients have not been determined; pharmacokinetic studies indicate that overall clinical responses remain high despite a low likelihood of pediatric patients attaining these targets (Chabala 2022; Tikiso 2022; Turkova 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">C<sub>max</sub> (2 hours after dose): 2 to 6 mg/L (Alsultan 2014; BTS [Haworth 2017]; Chabala 2022; Tikiso 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">AUC<sub>24</sub>: 16 to 29 mg•hour/L (Alsultan 2014; Chabala 2022; Tikiso 2022).</p></div>
<div class="block pha drugH1Div" id="F168012"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits arabinosyl transferase resulting in impaired mycobacterial cell wall synthesis</p></div>
<div class="block phk drugH1Div" id="F168029"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: ~80%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Widely throughout body; concentrated in kidneys, lungs, saliva, and red blood cells</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CSF:blood level ratio: Normal meninges: 0%; Inflamed meninges: 25%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 20% to 30%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic (20%) to inactive metabolite</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 2.5 to 3.6 hours; End-stage renal disease: 7 to 15 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 2 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~50% as unchanged drug, 8% to 15% as metabolites); feces (~20% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F58080640"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Clearance increases to 50% of full value by 2 months of age and reaches 99% of full value by 3 years of age (Tikiso 2022).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F168036"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Myambutol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Etambutol | Etambutol northia | Etambutol richet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Etibi | Myambutol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Myambutol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Etb | Ethamben | Fiambutol | Mycobac | Servambutol | Sural</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Myambutol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Etambutol | Ethambutol ds</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Furp etambutol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol labatec | Myambutol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol | Ethambutol hydrochloride | Sural</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ecox</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sural</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Emb | Emb fatol | Myambutol</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Luframbutol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Etambutol | Ethambutol | Myambutol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Emb fatol | Ethambutol | Oributol | Syntomen</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Etibi</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Etbutol | Ethambutol orion | Myambutol | Oributol | Stambutol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dexambutol | Ethambutol | Myambutol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol | Ethambutol kent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Myambutol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Emb fatol | Ethambutec | Ethambutol | Lambutol | Myambutol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Etambutol | Sural</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Sural</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Arsitam | Bacbutol | Butolex | Cetabutol | Corsabutol | Decabutol | Dexabutol | Ethambutol | Ethambutol Bernofarm | Etibi | Kalbutol | Myambutol | Ottobutol | Primbutol | Propar | Protibi | Santibi | Tibigon | Tibitol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Myambutol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Albutol | Anacox-e | Biobutol | Butacox | Cavibutol | Colbutol | Combutol | Concox | Ebutol | Ecox | Ethambutol | Ethatol | Fairbutol | Koxi | Koxylar | Lifebutol | Lincambutol | Ly butol | Marcobutol | Myambutol | Mycobact | Mycobutol | Mycostat | Ranbetol | Rptol | Sainbutol | Sunibutol | Synbutol | Themibutol | Tibitol | Tolbin | Ulticox | Ultiflox | Zytham</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Etapiam | Miambutol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ebutol | Esanbutol | Esanbutol hexal</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Ecox | Etham</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Esanbutol | Ethambutol | Korus ethambutol hcl | Myambutol | Tambutol | Tutol | Unibutol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Myambutol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Emb fatol | Etambulol atb | Etambutol | Ethambutol | Ly butol | Myambutol | Mycobutol | Sural</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Myambutol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol | Ly butol | Mycobutol | Sural</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol Pharma</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Brunibutol | Dovalem | Etambutol | Tambutec</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ambutol | Ebutol | Ecox | Ethambutol | Ethol | Etinol</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol | Surelife ethambutol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol Dihcl Fisher | Myambutol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Emb fatol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo-ethambutol | Emb fatol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Etambutol | Tibutol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">E Tol | Ethambin | Ethambutol hydrochloride | Hambutol | Odetol | Usa-ethambutol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Abbutol | Ambutol | Butal | Ethambutol | Etibi | Myambutol | Pire 1 | Schazobutol | Ubutol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol HCL | Ethambutol hydrochloride | Myambutol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Etambutol | Turresis</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Etambutol | Etambutol Atb</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Combutol | Ebutol | Ecox | Emb fatol | Ethambusin | Ethambutol | Ethambutol Akri | Ethambutol stada | Li butol | Ly butol | Mycobutol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Myambutol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ebutol | Ethambutol | Myambutol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Emb fatol | Etambutol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sural</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ambutol | Asiabutal | AT B | Conbutol | Dexambutol | Etham | Ethambutol | Ethbutol | Etibi | Lambutol | Mobutol | Myambutol | Servambutol | Tibitab | Tibitol | Tobutol | Tubertham</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dimbutol | Ethambutol | Miambutol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ambutol | E butol | Ebutol | Epbutol | Ethambutol | Ethambutol "p.l." | Etibi | Feramtol | Matamfe | Myambutol | Myambutol I/P | Winbutol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bruambutol | Combutol | Ecox | Enbutol | Ethambutol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Etham</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Myambutol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Vemarol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dyna ethambutol | Ethambutol | Myambutol | Rolab-ethambutol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ecox</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Ethambutol | Sandoz ethambutol | Thamtol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31844002">
<a name="31844002"></a>Abdelwahab MT, Leisegang R, Dooley KE, et al. Population pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in pregnant South African women with tuberculosis and HIV. <i>Antimicrob Agents Chemother.</i> 2020;64(3):e01978-19. doi:10.1128/AAC.01978-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/31844002/pubmed" id="31844002" target="_blank">31844002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8792014">
<a name="8792014"></a>Addis A, Blowey D, Koren G. Tuberculosis During Pregnancy. <i>Can Fam Physician</i>. 1996;42:1461-1462.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/8792014/pubmed" id="8792014" target="_blank">8792014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24846578">
<a name="24846578"></a>Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. <i>Drugs</i>. 2014;74(8):839-854. doi:10.1007/s40265-014-0222-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/24846578/pubmed" id="24846578" target="_blank">24846578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ATS.1">
<a name="ATS.1"></a>American Thoracic Society. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection,. <i>MMWR Recomm Rep</i>. 2000;49(RR-6):1-51.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26810651">
<a name="26810651"></a>Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines. <i>Antimicrob Agents Chemother</i>. 2016;60(4):2171-2179. doi:10.1128/AAC.02600-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/26810651/pubmed" id="26810651" target="_blank">26810651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8016763">
<a name="8016763"></a>British Thoracic Society. <i>Mycobacterium kansasii </i>pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. <i>Thorax</i>. 1994;49(5):442-445.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/8016763/pubmed" id="8016763" target="_blank">8016763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12836625">
<a name="12836625"></a>Centers for Disease Control and Prevention, “Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,” 2003,” <i>MMWR Recomm Rep</i>, 52(RR11):3-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/12836625/pubmed" id="12836625" target="_blank">12836625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23983702">
<a name="23983702"></a>Cernadas JR, Santos N, Pinto C, Mota PC, Castells M. Hypersensitivity reaction and tolerance induction to ethambutol. <i>Case Rep Med</i>. 2013;2013:208797. doi:10.1155/2013/208797<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/23983702/pubmed" id="23983702" target="_blank">23983702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34420049">
<a name="34420049"></a>Chabala C, Turkova A, Hesseling AC, et al. Pharmacokinetics of first-line drugs in children with tuberculosis, using World Health Organization-recommended weight band doses and formulations. <i>Clin Infect Dis</i>. 2022;74(10):1767-1775. doi:10.1093/cid/ciab725<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/34420049/pubmed" id="34420049" target="_blank">34420049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16495590">
<a name="16495590"></a>Chan RY, Kwok AK. Ocular toxicity of ethambutol. <i>Hong Kong Med J</i>. 2006;12(1):56-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/16495590/pubmed" id="16495590" target="_blank">16495590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28396542">
<a name="28396542"></a>Chew R, Jongbloed S, Jegatheesan D, et al. Ethambutol is cleared by a contemporary high-flux hemodialyzer, and drug monitoring ensures safety and therapeutic effect. <i>Antimicrob Agents Chemother</i>. 2017;61(6):e01988-16. doi:10.1128/AAC.01988-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/28396542/pubmed" id="28396542" target="_blank">28396542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35470602">
<a name="35470602"></a>Chung SJ, Byeon SJ, Choi JH. Analysis of adverse drug reactions to first-line anti-tuberculosis drugs using the Korea Adverse Event Reporting System. <i>J Korean Med Sci</i>. 2022;37(16):e128. doi:10.3346/jkms.2022.37.e128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/35470602/pubmed" id="35470602" target="_blank">35470602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32797222">
<a name="32797222"></a>Daley CL, Iaccarino JM, Lange C, e al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>Clin Infect Dis</i>. 2020;71(4):905-913. doi:10.1093/cid/ciaa1125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/32797222/pubmed" id="32797222" target="_blank">32797222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6121221">
<a name="6121221"></a>Ducobu J, DuPont P, Laurent M, et al. Acute Isoniazid/Ethambutol/Rifampicin Overdosage. <i>Lancet</i>. 1982;1(8272):632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/6121221/pubmed" id="6121221" target="_blank">6121221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29997980">
<a name="29997980"></a>Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. <i>J Thorac Dis</i>. 2018;10(5):3102-3118. doi:10.21037/jtd.2018.05.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/29997980/pubmed" id="29997980" target="_blank">29997980</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ethambutol hydrochloride [prescribing information]. Newtown, PA: STI Pharma LLC; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lupin.1">
<a name="Lupin.1"></a>Ethambutol tablet [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; February 2016.</div>
</li>
<li>
<div class="reference">
                  Etibi (ethambutol) [prescribing information]. Laval, Quebec, Canada: Bausch Health, Canada Inc; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26666259">
<a name="26666259"></a>Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society (CFF/ECFS) consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i>. 2016;71(suppl 1):i1-i22. doi:10.1136/thoraxjnl-2015-207360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/26666259/pubmed" id="26666259" target="_blank">26666259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1766519">
<a name="1766519"></a>García-Martín F, Mampaso F, de Arriba G, Moldenhauer F, Martín-Escobar E, Saíz F. Acute interstitial nephritis induced by ethambutol. <i>Nephron</i>. 1991;59(4):679-680. doi:10.1159/000186675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/1766519/pubmed" id="1766519" target="_blank">1766519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14557961">
<a name="14557961"></a>Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of <i>Mycobacterium kansasii</i> lung disease: results of a preliminary study. <i>Clin Infect Dis</i>. 2003;37(9):1178-1182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/14557961/pubmed" id="14557961" target="_blank">14557961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7673504">
<a name="7673504"></a>Grossman ME, Warren K, Mady A, Satra KH. Lichenoid eruption associated with ethambutol. <i>J Am Acad Dermatol</i>. 1995;33(4):675-676. doi:10.1016/0190-9622(95)91307-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/7673504/pubmed" id="7673504" target="_blank">7673504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9929528">
<a name="9929528"></a>Havlir DV, Barnes PF. Tuberculosis in Patients With Human Immunodeficiency Virus Infection. <i>N Engl J Med</i>. 1999;340(5):367-373.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/9929528/pubmed" id="9929528" target="_blank">9929528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054853">
<a name="29054853"></a>Haworth CS, Banks J, Capstick T, et al. British Thoracic Society (BTS) guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). <i>Thorax</i>. 2017;72(suppl 2):ii1-ii64. doi:10.1136/thoraxjnl-2017-210927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/29054853/pubmed" id="29054853" target="_blank">29054853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35766120">
<a name="35766120"></a>Huang YW, Wu WH. Ethambutol-induced subacute cutaneous lupus erythematosus. <i>Kaohsiung J Med Sci</i>. 2022;38(9):914-915. doi:10.1002/kjm2.12571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/35766120/pubmed" id="35766120" target="_blank">35766120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35168714">
<a name="35168714"></a>Jaganath D, Beaudry J, Salazar-Austin N. Tuberculosis in children. <i>Infect Dis Clin North Am</i>. 2022;36(1):49-71. doi:10.1016/j.idc.2021.11.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/35168714/pubmed" id="35168714" target="_blank">35168714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203783">
<a name="28203783"></a>Johnston JC, Campbell JR, Menzies D. Effect of intermittency on treatment outcomes in pulmonary tuberculosis: an updated systematic review and metaanalysis. <i>Clin Infect Dis</i>. 2017;64(9):1211-1220. doi:10.1093/cid/cix121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/28203783/pubmed" id="28203783" target="_blank">28203783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30848209">
<a name="30848209"></a>Kapur A, Rehan HS. Drug reaction with eosinophilia and systemic symptoms syndrome associated with ethambutol use: a case report. <i>Curr Drug Saf</i>. 2019;14(3):249-251. doi:10.2174/1574886314666190307150757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/30848209/pubmed" id="30848209" target="_blank">30848209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35295035">
<a name="35295035"></a>Kollipara VK, Horowitz M, Lantz J, Nagy-Agren S. Ethambutol-induced bullous skin lesions in <i>mycobacterium kansasii</i> lung infection. <i>Int J Mycobacteriol</i>. 2022;11(1):120-122. doi:10.4103/ijmy.ijmy_204_21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/35295035/pubmed" id="35295035" target="_blank">35295035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15102986">
<a name="15102986"></a>Kwon SH, Kim JH, Yang JO, Lee EY, Hong SY. Ethambutol-induced acute renal failure. <i>Nephrol Dial Transplant</i>. 2004;19(5):1335-1336. doi:10.1093/ndt/gfh166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/15102986/pubmed" id="15102986" target="_blank">15102986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35582729">
<a name="35582729"></a>Kyncl M, Fus M, Lestak J. Ethambutol-induced optic neuropathy. <i>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</i>. 2023;167(3):288-293. doi:10.5507/bp.2022.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/35582729/pubmed" id="35582729" target="_blank">35582729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Loeffler.1">
<a name="Loeffler.1"></a>Loeffler AM, Gaensbauer J, Dasgupta-Tsinikas S, Wendorf K. Pediatrics. In: <i>Drug-resistant Tuberculosis: A Survival Guide for Clinicians, Third edition/2022 Updates</i>. Curry International Tuberculosis Center and California Department of Public Health; 2022: chap. 6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10228130">
<a name="10228130"></a>Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. <i>Am J Respir Crit Care Med</i>. 1999;159(5, pt 1):1580-1584. doi:10.1164/ajrccm.159.5.9810034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/10228130/pubmed" id="10228130" target="_blank">10228130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459437">
<a name="32459437"></a>Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. <i>Obstet Gynecol.</i> 2020;135(6):1444-1453. doi:10.1097/AOG.0000000000003890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/32459437/pubmed" id="32459437" target="_blank">32459437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25861347">
<a name="25861347"></a>Moon KM, Han MS, Chung SH, et al. Agranulocytosis induced by ethambutol in a patient with pulmonary tuberculosis. <i>Tuberc Respir Dis (Seoul)</i>. 2015;78(2):125-127. doi:10.4046/trd.2015.78.2.125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/25861347/pubmed" id="25861347" target="_blank">25861347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27516382">
<a name="27516382"></a>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America (ATS/CDC/IDSA) clinical practice guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-e195. doi:10.1093/cid/ciw376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/27516382/pubmed" id="27516382" target="_blank">27516382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31729908">
<a name="31729908"></a>Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. <i>Am J Respir Crit Care Med</i>. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/31729908/pubmed" id="31729908" target="_blank">31729908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7305578">
<a name="7305578"></a>Pegram PS Jr, Mountz JD, O'Bar PR. Ethambutol-induced toxic epidermal necrolysis. <i>Arch Intern Med</i>. 1981;141(12):1677-1678.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/7305578/pubmed" id="7305578" target="_blank">7305578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17638210">
<a name="17638210"></a>Peloquin CA, Durbin D, Childs J, Sterling TR, Weiner M. Stability of antituberculosis drugs mixed in food. <i>Clin Infect Dis</i>. 2007;45(4):521. doi:10.1086/520011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/17638210/pubmed" id="17638210" target="_blank">17638210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19561898">
<a name="19561898"></a>Prasad R, Garg R, Verma SK. Isoniazid- and ethambutol-induced psychosis. <i>Ann Thorac Med</i>. 2008;3(4):149-151. doi:10.4103/1817-1737.43083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/19561898/pubmed" id="19561898" target="_blank">19561898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9809743">
<a name="9809743"></a>Prevention and Treatment of Tuberculosis Among Patients Infected With Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. Centers for Disease Control and Prevention. <i>MMWR Recomm Rep</i>. 1998;47(RR-20):1-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/9809743/pubmed" id="9809743" target="_blank">9809743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24250213">
<a name="24250213"></a>Saha K, Bandyopadhyay A, Sengupta A, Jash D. A rare case of ethambutol induced pulmonary eosinophilia. <i>J Pharmacol Pharmacother</i>. 2013;4(4):300-302. doi:10.4103/0976-500X.119724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/24250213/pubmed" id="24250213" target="_blank">24250213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24196753">
<a name="24196753"></a>Scoville BA, De Lott LB, Trobe JD, Mueller BA. Ethambutol optic neuropathy in a hemodialysis patient receiving a guideline-recommended dose. <i>J Neuroophthalmol</i>. 2013;33(4):421-423. doi:10.1097/wno.0000000000000075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/24196753/pubmed" id="24196753" target="_blank">24196753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16537880">
<a name="16537880"></a>Shitrit D, Baum GL, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. <i>Chest</i>. 2006;129(3):771-776.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/16537880/pubmed" id="16537880" target="_blank">16537880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-516170">
<a name="516170"></a>Shneerson JM, Francis RS. Ethambutol in pregnancy--foetal exposure. <i>Tubercle</i>. 1979;60(3):167-169. doi:10.1016/0041-3879(79)90018-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/516170/pubmed" id="516170" target="_blank">516170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29776936">
<a name="29776936"></a>Si M, Li H, Chen Y, Peng H. Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis. <i>BMJ Case Rep</i>. 2018;2018:bcr2017223187. doi:10.1136/bcr-2017-223187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/29776936/pubmed" id="29776936" target="_blank">29776936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26518065">
<a name="26518065"></a>Strunk AK, Ciesek S, Schmidt JJ, et al. Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. <i>Int J Infect Dis</i>. 2016;42:1-3. doi:10.1016/j.ijid.2015.10.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/26518065/pubmed" id="26518065" target="_blank">26518065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9389304">
<a name="9389304"></a>Takami A, Nakao S, Asakura H, et al. Pneumonitis and eosinophilia induced by ethambutol. <i>J Allergy Clin Immunol</i>. 1997;100(5):712-713. doi:10.1016/s0091-6749(97)70178-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/9389304/pubmed" id="9389304" target="_blank">9389304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35466379">
<a name="35466379"></a>Tikiso T, McIlleron H, Abdelwahab MT, et al. Population pharmacokinetics of ethambutol in African children: a pooled analysis. <i>J Antimicrob Chemother</i>. 2022;77(7):1949-1959. doi:10.1093/jac/dkac127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/35466379/pubmed" id="35466379" target="_blank">35466379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LTBI.1">
<a name="LTBI.1"></a>Treatment of Latent Tuberculosis Infection (LTBI), Last Updated: April 8, 2004. <a href="https://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm" target="_blank">http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm</a>. Accessed February 16, 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35263517">
<a name="35263517"></a>Turkova A, Wills GH, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. <i>N Engl J Med</i>. 2022;386(10):911-922. doi:10.1056/NEJMoa2104535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/35263517/pubmed" id="35263517" target="_blank">35263517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Children with and Exposed to HIV. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. Available at <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection</a>. Updated September 2, 2022. Accessed April 18, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2020">
<a name="HHS.2020"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Accessed April 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Accessed June 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.5">
<a name="HHS.5"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Updated January 18, 2023. Accessed April 18, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7956448">
<a name="7956448"></a>Wong CF, Yew WW. Ethambutol-induced neutropenia and eosinophilia. <i>Chest</i>. 1994;106(5):1638-1639. doi:10.1378/chest.106.5.1638<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/7956448/pubmed" id="7956448" target="_blank">7956448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7656964">
<a name="7656964"></a>Wong PC, Yew WW, Wong CF, Choi HY. Ethambutol-induced pulmonary infiltrates with eosinophilia and skin involvement. <i>Eur Respir J</i>. 1995;8(5):866-868.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/7656964/pubmed" id="7656964" target="_blank">7656964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en/. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. 2014a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.3">
<a name="WHO.3"></a>World Health Organization (WHO). Treatment of tuberculosis guidelines. 4th edition. 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.4">
<a name="WHO.4"></a>World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. https://www.who.int/publications/i/item/9789240007048. Published 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.5">
<a name="WHO.5"></a>World Health Organization (WHO). WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. https://www.who.int/publications/i/item/9789240046764. Published September 21, 2022a. Accessed April 18, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25320836">
<a name="25320836"></a>World Health Organization (WHO). Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization; 2014b.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/25320836/pubmed" id="25320836" target="_blank">25320836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.6">
<a name="WHO.6"></a>World Health Organization (WHO). WHO operational handbook on tuberculosis: module 5: management of tuberculosis in children and adolescents. https://www.who.int/publications/i/item/9789240046832. Published March 17, 2022b. Accessed April 18, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1740604">
<a name="1740604"></a>Yoshikawa TT. Tuberculosis in Aging Adults. <i>J Am Geriatr Soc</i>. 1992;40(2):178-187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/1740604/pubmed" id="1740604" target="_blank">1740604</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13286 Version 208.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
